Skip to main content

Table 2 Treatment-related toxicity

From: GNAS mutations as prognostic biomarker in patients with relapsed peritoneal pseudomyxoma receiving metronomic capecitabine and bevacizumab: a clinical and translational study

Adverse events

N° of patients (%) grade according NCI-CTC vers. 4.03

G1

G2

G3

G4

Hypertension

–

1 (6 %)

1 (6 %)

–

Thromboembolic event

–

1 (6 %)

1 (6 %)

–

Diarrhea

2 (13 %)

1 (6 %)

–

–

Neutropenia

–

1 (6 %)

–

–

Hand Foot Syndrome

–

1 (6 %)

1 (6 %)

–

Epistaxis

1 (6 %)

–

–

–

Fatigue

2 (13 %)

–

–

–

  1. NCI-CTC, National Cancer Institute—Common Toxicity Criteria